Navigation Links
First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
Date:4/21/2009

- Company plans initiation of clinical studies; Data to be presented at AACR -

BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of clinical trials in cancer. EP-100 is the first candidate from the Company's Cationic Lytic Peptide (CLYP(TM)) platform technology. EP-100 is a targeted membrane-disrupting peptide and is designed to selectively target luteinizing hormone releasing hormone (LHRH) receptors, which are overexpressed in a wide range of cancers. Results from preclinical in vitro and in vivo studies of EP-100 in ovarian cancer cell lines and ovarian xenograft models were presented in a poster presentation entitled, "Targeted Oncolytic Peptide for Treatment of Ovarian Cancers" at the American Association for Cancer Research (AACR) Annual Meeting in Denver, CO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090421/NE02455LOGO )

Esperance is using its CLYP(TM) technology to develop a robust portfolio of small, novel oncolytic peptides to selectively destroy cancer cells that express target receptors. In addition to EP-100, the Company is developing several other drug candidates, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively to cancer cells that express the target receptors on their surfaces. The positively charged peptides disrupt the negatively charged membranes of the cancer cells, causing rapid cell death by lysis.

"These data not only support the continued development of EP-100, but also validate our core membrane-disrupting peptide platform technology," said Carola Leuschner, P
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oakwood Surgeons Perform Worlds First 3D Surgery Without Special Glasses
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
4. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
5. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
6. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
7. First Human Study to Show Sun Chlorella A Supports Heart Health
8. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
9. First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008
10. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
11. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... 2011 Endologix, Inc. (NASDAQ: ELGX ), developer ... financial results for the three and six months ended June ... Executive Officer, said, "We are pleased with our progress during ... and new product development goals for 2011.  In the second ...
... July 21, 2011 Cardiac Science Corporation ... (AEDs) and diagnostic cardiac monitoring devices that connect ... systems, announced today the new capability of direct ... and the GE Healthcare Centricity® EMR system. ...
Cached Medicine Technology:Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9Cardiac Science Expands Device Connectivity Solutions 2Cardiac Science Expands Device Connectivity Solutions 3
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... that is helping people perform better in and out of ... performance, and memory has caught the attention of Shane Michaels, ... the day-to-day grind, fatigue is the reason most people simply ... want, whether that means staying focused at work, getting the ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... providers in Turkey has gone up more than 79 ... The medical tourism company also reported total revenue tripled ... 2012. , The company’s professional strategy has allowed them ... — ultimately designed for patient comfort and privacy — ...
(Date:9/30/2014)... September 30, 2014 Hospice & ... annual “In Celebration” gala, honoring three outstanding individuals ... of striving to provide extraordinary and dignified comfort, ... a serious or life-limiting illness. , The event ... Rye, NY and recognized William (Bill) J. McGuinness, ...
(Date:9/30/2014)... 30, 2014 Regenerative Medicine Solutions (RMS) ... clinics in Nashville, Tennessee. RMS welcomes the launch of ... the expansion of a new treatment center for the ... Sleep Apnea Institute to Nashville, the hope is to ... apnea: both diagnosed and undiagnosed. With Nashville being a ...
Breaking Medicine News(10 mins):Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2
... All 90 Inspected Pennsylvania Facilities Meet Federal StandardsHARRISBURG, ... Protection released reports today showing that all of ... fourth quarter of 2008 are operating within the ... Drug Administration.DEP inspects each of Pennsylvania,s approximately 400 ...
... The annual Bio-IT World Conference & Expo will be held April 27-29, ... debut in 2002, the Expo has established itself as the premier event ... the drug discovery enterprise. The Expo is the perfect place to ... ...
... (Nasdaq: MYL ) today announced that its Vice ... NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 ... to celebrate the company,s switch from The New York Stock ... Dec. 29, 2008. The company is listed on the NASDAQ ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... low-dose aspirin-induced peptic ulcer seems to be increasing in ... individuals, in whom metabolic syndrome frequently develops. However, a ... not yet been established. , A research team led ... Their study will be published on February 14, 2009 ...
... are defined as leading an active or inactive lifestyle ... which guideline your GP picks off the shelf, say ... countries have guidelines recommending the minimum amount of physical ... of this advice is conflicting, making it difficult for ...
Cached Medicine News:Health News:PA DEP Releases Quarterly Mammography Inspections 2Health News:PA DEP Releases Quarterly Mammography Inspections 3Health News:PA DEP Releases Quarterly Mammography Inspections 4Health News:Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine 2Health News:Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine 3Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:What is the most effective therapy for low-dose aspirin induced peptic ulcer? 2Health News:Physical activity guidelines are too confusing, say researchers 2
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... Katena Products, Inc. is ... company dedicated exclusively to ophthalmic ... products to over 7,000 customers ... through a global network of ...
... food, exercise, stress . . . Theyre ... overall health. Unfortunately, its difficult, and often ... on a daily basis. Its even more ... submit the information to a care provider ...
... Managing diabetes requires making decisions about insulin ... exercise. These decisions are guided by data ... information, and by the patterns that can ... Care Providers when the data is presented ...
Medicine Products: